Skip to main content
Top
Published in: Acta Diabetologica 5/2014

01-10-2014 | Original Article

Prevention of type 2 diabetes in obese at-risk subjects: a systematic review and meta-analysis

Authors: Claudia Merlotti, Alberto Morabito, Valerio Ceriani, Antonio E. Pontiroli

Published in: Acta Diabetologica | Issue 5/2014

Login to get access

Abstract

Different intervention strategies can prevent new cases of type 2 diabetes (T2DM) in obese subjects. The present systematic review and meta-analysis evaluates the effectiveness of different strategies in prevention of type 2 diabetes in obese subjects. Studies were grouped into five different strategies: (1) physical activity ± diet; (2) anti-diabetic drugs (glitazones, metformin, glinides, alfa-glucosidase inhibitors); (3) antihypertensive drugs (ACE inhibitors, ARB); (4) weight loss-promoting drugs and lipid-lowering drugs (orlistat, bezafibrate, phentermine/topiramate controlled release); and (5) bariatric surgery. Only controlled studies, dealing with subjects BMI ≥ 30 kg/m2, were included in the analysis, whether randomized or non-randomized studies. Appropriate methodology (PRISMA statement) was adhered to. Publication bias was formally assessed. Eighteen studies (43,669 subjects, 30,774 with impaired glucose tolerance and/or impaired fasting glucose), published in English language as full papers, were analyzed to identify predictors of new cases of T2DM and were included in a meta-analysis (random-effects model) to study the effect of different strategies. Intervention effect (new cases of diabetes) was expressed as odds ratio (OR), with 95 % confidence intervals (CIs). In obese subjects, non-surgical strategies were able to prevent T2DM, with different effectiveness [OR from 0.44 (0.36–0.52) to 0.86 (0.80–0.92)]; in morbidly obese subjects, bariatric surgery was highly effective [OR = 0.10 (0.02–0.49)]. At meta-regression analysis, factors associated with effectiveness were weight loss, young age and fasting insulin levels. Publication bias was present only when considering all studies together. These data indicate that several strategies, with different effectiveness, can prevent T2DM in obese subjects.
Appendix
Available only for authorised users
Literature
3.
4.
go back to reference Ford ES, Zhao G, Li C et al (2010) Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 55:1310–1317PubMedCrossRef Ford ES, Zhao G, Li C et al (2010) Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 55:1310–1317PubMedCrossRef
5.
go back to reference Cheng YJ, Gregg EW, Geiss LS et al (2009) Association of HbA1c and fasting plasma glucose level with diabetic retinopathy prevalence in the U.S. population: implication for diabetes diagnostic thresholds. Diabetes Care 32:2027–2032PubMedCrossRefPubMedCentral Cheng YJ, Gregg EW, Geiss LS et al (2009) Association of HbA1c and fasting plasma glucose level with diabetic retinopathy prevalence in the U.S. population: implication for diabetes diagnostic thresholds. Diabetes Care 32:2027–2032PubMedCrossRefPubMedCentral
6.
go back to reference Ziegler D, Rathmann W, Dickhaus T et al (2008) Prevalence of polyneuropathy in prediabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Survey S2 and S3. Diabetes Care 31:464–469PubMedCrossRef Ziegler D, Rathmann W, Dickhaus T et al (2008) Prevalence of polyneuropathy in prediabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Survey S2 and S3. Diabetes Care 31:464–469PubMedCrossRef
7.
go back to reference CDC. Diabetes Fact Sheet online 2011. Jan 26.2011 CDC. Diabetes Fact Sheet online 2011. Jan 26.2011
8.
go back to reference American Diabetes Association (2012) Standards of medical care in diabetes-2012. Diabetes Care 35:S11–S63CrossRef American Diabetes Association (2012) Standards of medical care in diabetes-2012. Diabetes Care 35:S11–S63CrossRef
9.
go back to reference Nathan DM, Davidson MB, DeFronzo RA et al (2007) Impaired fasting glucose and impaired glucose tolerance: implication for care. Diabetes Care 30:753–759PubMedCrossRef Nathan DM, Davidson MB, DeFronzo RA et al (2007) Impaired fasting glucose and impaired glucose tolerance: implication for care. Diabetes Care 30:753–759PubMedCrossRef
10.
go back to reference Brakis G, Stockert J, Molitch M et al (2009) Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab 11:177–187CrossRef Brakis G, Stockert J, Molitch M et al (2009) Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab 11:177–187CrossRef
12.
go back to reference Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311–321PubMedCrossRef Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311–321PubMedCrossRef
13.
go back to reference Perrault L, Pan Q, Mather KJ et al (2012) Regression from pre-diabetes to normal glucose regulation is associated with long term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 379:2243–2251CrossRef Perrault L, Pan Q, Mather KJ et al (2012) Regression from pre-diabetes to normal glucose regulation is associated with long term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 379:2243–2251CrossRef
14.
go back to reference Phung OJ, Sood NA, Sill BE, Coleman CI (2011) Oral anti-diabetic drugs for the prevention of type 2 diabetes. Diabet Med 28:948–964PubMedCrossRef Phung OJ, Sood NA, Sill BE, Coleman CI (2011) Oral anti-diabetic drugs for the prevention of type 2 diabetes. Diabet Med 28:948–964PubMedCrossRef
15.
go back to reference Knowler WC, Barrett-Connor E, Fowler SE, The Diabetes Prevention Program Research Group et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCrossRef Knowler WC, Barrett-Connor E, Fowler SE, The Diabetes Prevention Program Research Group et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCrossRef
16.
go back to reference Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S et al (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368:1673–1679PubMedCrossRef Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S et al (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368:1673–1679PubMedCrossRef
17.
go back to reference Penn L, White M, Oldroyd J et al (2009) Prevention 006Ff type 2 diabetes in adults with impaired glucose tolerance: the European diabetes prevention RCT in newcastle upon Tyne UK. BMC Public Health 9:342PubMedCrossRefPubMedCentral Penn L, White M, Oldroyd J et al (2009) Prevention 006Ff type 2 diabetes in adults with impaired glucose tolerance: the European diabetes prevention RCT in newcastle upon Tyne UK. BMC Public Health 9:342PubMedCrossRefPubMedCentral
18.
go back to reference Penn L, White M, Lindstrom J, den Boer A et al (2013) Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of the European Diabetes Prevention Study RCT. PLoS One 8:e57143PubMedCrossRefPubMedCentral Penn L, White M, Lindstrom J, den Boer A et al (2013) Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of the European Diabetes Prevention Study RCT. PLoS One 8:e57143PubMedCrossRefPubMedCentral
19.
go back to reference Buchanan TA, Xiang AH, Peters RK et al (2002) Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high–risk Hispanic women. Diabetes 51:2796–2803PubMedCrossRef Buchanan TA, Xiang AH, Peters RK et al (2002) Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high–risk Hispanic women. Diabetes 51:2796–2803PubMedCrossRef
20.
go back to reference Chiasson JL, Josse RG, Gomis R (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077PubMedCrossRef Chiasson JL, Josse RG, Gomis R (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077PubMedCrossRef
21.
go back to reference Gerstein HC, Yusuf S, Bosch J, The Dream Trial Investigators et al (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096–1105PubMedCrossRef Gerstein HC, Yusuf S, Bosch J, The Dream Trial Investigators et al (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096–1105PubMedCrossRef
22.
go back to reference Holman RR, Haffner SM, McMurray JJ, The NAVIGATOR Study Group et al (2010) Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1463–1476PubMedCrossRef Holman RR, Haffner SM, McMurray JJ, The NAVIGATOR Study Group et al (2010) Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1463–1476PubMedCrossRef
23.
go back to reference DeFronzo RA, Tripathy D, Schwenke DC, The ACT NOW Study et al (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364:1104–1115PubMedCrossRef DeFronzo RA, Tripathy D, Schwenke DC, The ACT NOW Study et al (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364:1104–1115PubMedCrossRef
24.
go back to reference Gerstein HC, Mohan V, Avezum A et al (2011) Long term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia 54:487–495PubMedCrossRef Gerstein HC, Mohan V, Avezum A et al (2011) Long term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia 54:487–495PubMedCrossRef
25.
go back to reference Bosch J, Yusuf S, Gerstein HC, For the Dream Trial Investigators et al (2006) Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551–1562PubMedCrossRef Bosch J, Yusuf S, Gerstein HC, For the Dream Trial Investigators et al (2006) Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551–1562PubMedCrossRef
26.
go back to reference Mc Murray JJ, Holman RR, Haffner SM et al (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1477–1490CrossRef Mc Murray JJ, Holman RR, Haffner SM et al (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1477–1490CrossRef
27.
go back to reference Torgerson JS, Hauptman J, Boldrin MN et al (2004) XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27:155–161PubMedCrossRef Torgerson JS, Hauptman J, Boldrin MN et al (2004) XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27:155–161PubMedCrossRef
28.
go back to reference Tenenbaum A, Motro M, Fisman EZ et al (2005) Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 26:2032–2038PubMedCrossRef Tenenbaum A, Motro M, Fisman EZ et al (2005) Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 26:2032–2038PubMedCrossRef
29.
go back to reference Garvey T, Ryan DH, Henry R et al (2014) Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome with phentermine and topiramate extended-release. Diabetes Care 37:912–921PubMedCrossRef Garvey T, Ryan DH, Henry R et al (2014) Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome with phentermine and topiramate extended-release. Diabetes Care 37:912–921PubMedCrossRef
30.
go back to reference Long SD, O’Brien K, MacDonald KG et al (1994) Weight loss in severely obese subjects prevents progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care 17:372–375PubMedCrossRef Long SD, O’Brien K, MacDonald KG et al (1994) Weight loss in severely obese subjects prevents progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care 17:372–375PubMedCrossRef
31.
go back to reference Pontiroli AE, Folli F, Paganelli M et al (2005) Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity. A 4-year case-controlled study. Diabetes Care 28:2703–2709PubMedCrossRef Pontiroli AE, Folli F, Paganelli M et al (2005) Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity. A 4-year case-controlled study. Diabetes Care 28:2703–2709PubMedCrossRef
32.
go back to reference Carlsson LM, Peltonen M, Ahlin S et al (2012) Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 367:695–704PubMedCrossRef Carlsson LM, Peltonen M, Ahlin S et al (2012) Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 367:695–704PubMedCrossRef
33.
go back to reference Yamaoka K, Tango T (2005) Efficacy of lifestyle education to prevent type 2 diabetes. A meta-analysis of randomized controlled trials. Diabetes Care 28:2780–2786PubMedCrossRef Yamaoka K, Tango T (2005) Efficacy of lifestyle education to prevent type 2 diabetes. A meta-analysis of randomized controlled trials. Diabetes Care 28:2780–2786PubMedCrossRef
34.
go back to reference Norris SL, Zhang X, Avenell A et al (2005) Long term effectiveness of weight-loss interventions in adults with pre-diabetes. A review. Am J Prev Med 28:126–139PubMedCrossRef Norris SL, Zhang X, Avenell A et al (2005) Long term effectiveness of weight-loss interventions in adults with pre-diabetes. A review. Am J Prev Med 28:126–139PubMedCrossRef
35.
go back to reference Lloret-Linares C, Greenfield JR, Czernichow S (2008) Effect of weight reducing agents on glycaemic parameters and progression to type 2 diabetes: a review. Diabet Med 25:1142–1150PubMedCrossRef Lloret-Linares C, Greenfield JR, Czernichow S (2008) Effect of weight reducing agents on glycaemic parameters and progression to type 2 diabetes: a review. Diabet Med 25:1142–1150PubMedCrossRef
36.
go back to reference Yates T, Khunti K, Bull F et al (2007) The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia 50:1116–1126PubMedCrossRefPubMedCentral Yates T, Khunti K, Bull F et al (2007) The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia 50:1116–1126PubMedCrossRefPubMedCentral
37.
go back to reference Anderson DC (2005) Pharmacologic prevention or delay of type 2 diabetes mellitus. Ann Pharmacother 39:102–109PubMedCrossRef Anderson DC (2005) Pharmacologic prevention or delay of type 2 diabetes mellitus. Ann Pharmacother 39:102–109PubMedCrossRef
38.
go back to reference Padwal R, Majumdar SR, Johnson JA et al (2005) A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 28:736–744PubMedCrossRef Padwal R, Majumdar SR, Johnson JA et al (2005) A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 28:736–744PubMedCrossRef
39.
go back to reference Abuissa H, Jones PG, Marso SP, O’Keefe JH Jr (2005) Angiotensin-Converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 46:821–826PubMedCrossRef Abuissa H, Jones PG, Marso SP, O’Keefe JH Jr (2005) Angiotensin-Converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 46:821–826PubMedCrossRef
40.
go back to reference Andraws R, Brown DL (2007) Effect of inhibitors of the renin-angiotensin system on the development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 99:1006–1012PubMedCrossRef Andraws R, Brown DL (2007) Effect of inhibitors of the renin-angiotensin system on the development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 99:1006–1012PubMedCrossRef
41.
go back to reference Abuissa H, O’Keefe J (2008) The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection. Diabetes Obes Metab 10:1157–1166PubMed Abuissa H, O’Keefe J (2008) The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection. Diabetes Obes Metab 10:1157–1166PubMed
42.
go back to reference Higgins JPT, Green S (eds) (2008) Cochrane handbook for systematic reviews. Special topics in statistics: studies with more than two intervention groups. Wiley, Blackwell Higgins JPT, Green S (eds) (2008) Cochrane handbook for systematic reviews. Special topics in statistics: studies with more than two intervention groups. Wiley, Blackwell
43.
go back to reference Higgins JPT, Altman DG, Gotzsche PC, Juni P et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928PubMedCrossRefPubMedCentral Higgins JPT, Altman DG, Gotzsche PC, Juni P et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928PubMedCrossRefPubMedCentral
44.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG (2009) PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097PubMedCrossRefPubMedCentral Moher D, Liberati A, Tetzlaff J, Altman DG (2009) PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097PubMedCrossRefPubMedCentral
45.
47.
go back to reference Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR (1991) Publication bias in clinical research. Lancet 337:867–872PubMedCrossRef Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR (1991) Publication bias in clinical research. Lancet 337:867–872PubMedCrossRef
48.
go back to reference Lim E, Ali Z, Ali A, Routledge T, Edmonds L, Altman DG, Large S (2007) Indirect comparison meta-analysis of aspirin therapy after coronary surgery. BMJ 327:1–5 Lim E, Ali Z, Ali A, Routledge T, Edmonds L, Altman DG, Large S (2007) Indirect comparison meta-analysis of aspirin therapy after coronary surgery. BMJ 327:1–5
49.
go back to reference Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375:735–742PubMedCrossRef Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375:735–742PubMedCrossRef
50.
go back to reference Scheen AJ (2007) Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes? Diabetes Metab 33:3–12PubMedCrossRef Scheen AJ (2007) Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes? Diabetes Metab 33:3–12PubMedCrossRef
51.
go back to reference Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I (2009) Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 122(248–256):e5PubMed Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I (2009) Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 122(248–256):e5PubMed
52.
go back to reference Arterburn DE, Bogart A, Sherwood NE, Sidney S, Coleman KJ, Haneuse S, O’Connor PJ, Theis MK, Campos GM, McCulloch D, Selby J (2013) A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 23:93–102PubMedCrossRef Arterburn DE, Bogart A, Sherwood NE, Sidney S, Coleman KJ, Haneuse S, O’Connor PJ, Theis MK, Campos GM, McCulloch D, Selby J (2013) A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 23:93–102PubMedCrossRef
53.
go back to reference Diabetes Prevention Program Research Group (2003) Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 26:977–980CrossRef Diabetes Prevention Program Research Group (2003) Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 26:977–980CrossRef
54.
go back to reference Pontiroli AE, Merlotti C, Veronelli A, Lombardi F (2013) Effect of weight loss on sympatho-vagal balance in subjects with grade-3 obesity: restrictive surgery versus hypocaloric diet. Acta Diabetol 50:843–850PubMedCrossRef Pontiroli AE, Merlotti C, Veronelli A, Lombardi F (2013) Effect of weight loss on sympatho-vagal balance in subjects with grade-3 obesity: restrictive surgery versus hypocaloric diet. Acta Diabetol 50:843–850PubMedCrossRef
55.
go back to reference Folini L, Veronelli A, Benetti A, Pozzato C, Cappelletti M, Masci E, Micheletto G, Pontiroli AE (2014) Liver steatosis (LS) evaluated through chemical-shift magnetic resonance imaging liver enzymes in morbid obesity; effect of weight loss obtained with intragastric balloon gastric banding. Acta Diabetol 51(3):361–368PubMedCrossRef Folini L, Veronelli A, Benetti A, Pozzato C, Cappelletti M, Masci E, Micheletto G, Pontiroli AE (2014) Liver steatosis (LS) evaluated through chemical-shift magnetic resonance imaging liver enzymes in morbid obesity; effect of weight loss obtained with intragastric balloon gastric banding. Acta Diabetol 51(3):361–368PubMedCrossRef
56.
go back to reference Adams ST, Salhab M, Hussain ZI, Miller GV, Leveson SH (2013) Preoperatively determinable factors predictive of diabetes mellitus remission following Roux-en-Y gastric bypass: a review of the literature. Acta Diabetol 50:475–478PubMedCrossRef Adams ST, Salhab M, Hussain ZI, Miller GV, Leveson SH (2013) Preoperatively determinable factors predictive of diabetes mellitus remission following Roux-en-Y gastric bypass: a review of the literature. Acta Diabetol 50:475–478PubMedCrossRef
Metadata
Title
Prevention of type 2 diabetes in obese at-risk subjects: a systematic review and meta-analysis
Authors
Claudia Merlotti
Alberto Morabito
Valerio Ceriani
Antonio E. Pontiroli
Publication date
01-10-2014
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 5/2014
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-014-0624-9

Other articles of this Issue 5/2014

Acta Diabetologica 5/2014 Go to the issue